ADMA Biologics: Under-The-Radar Biotech With Huge Potential Upside
(WorldNews Health)

ADMA Biologics (ADMA) has racked up two big FDA wins in the past couple months. In April, it received FDA approval for Asceniv, an intravenous immune globulin (`IVIG`) drug product for the treatment of Primary Humoral Immunodeficiency Disease (`PI`). In May, the FDA gave the nod to another of ADMA´s PI therapies, Bivigam. Together, these approvals represent a major step forward for ADMA. The stock is up nearly 75% since the start of the year, but even that impressive run-up appears likely to be just the beginning of a much bigger upward run to come. Bivigam and Asceniv should find ready demand in the rapidly growing, supply-constrained IVIG market. Bivigam: A Long Road Back to Market Getting...